Timothy Vollmer mainly focuses on Internal medicine, Multiple sclerosis, Surgery, Placebo and Randomized controlled trial. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Cardiology. His research on Multiple sclerosis concerns the broader Immunology.
His studies examine the connections between Surgery and genetics, as well as such issues in Glatiramer acetate, with regards to Placebo-controlled study. Timothy Vollmer combines subjects such as Adverse effect and Randomization with his study of Placebo. His work is dedicated to discovering how Randomized controlled trial, Clinical trial are connected with Chemotherapy and Natalizumab and other disciplines.
His primary scientific interests are in Multiple sclerosis, Internal medicine, Immunology, Physical therapy and Placebo. His work on Glatiramer acetate, Natalizumab and Relapsing remitting as part of general Multiple sclerosis study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Fingolimod and Surgery.
His studies deal with areas such as Logistic regression, Quality of life, Physical medicine and rehabilitation and Comorbidity as well as Physical therapy. In his research, Clinical trial is intimately related to Randomized controlled trial, which falls under the overarching field of Placebo. His Clinical endpoint study frequently intersects with other fields, such as Expanded Disability Status Scale.
Timothy Vollmer mostly deals with Multiple sclerosis, Internal medicine, Fingolimod, Adverse effect and Physical therapy. His Multiple sclerosis research is multidisciplinary, incorporating elements of Placebo and Atrophy. His Internal medicine research focuses on subjects like Gastroenterology, which are linked to Lesion.
In Fingolimod, Timothy Vollmer works on issues like Dimethyl fumarate, which are connected to Tolerability and Pharmacology. His research in Adverse effect focuses on subjects like Incidence, which are connected to Abdominal pain, JC virus, Immunocompetence, Progressive multifocal leukoencephalopathy and Immunodeficiency. His research integrates issues of Quality of life, Physical medicine and rehabilitation, Cognitive test and Paced Auditory Serial Addition Test in his study of Physical therapy.
His primary areas of study are Multiple sclerosis, Internal medicine, Placebo, Fingolimod and Randomized controlled trial. His study of Glatiramer acetate is a part of Multiple sclerosis. His Glatiramer acetate research includes elements of Cancer research, Active disease, Clinical endpoint, Rituximab and Induction therapy.
His research on Internal medicine often connects related topics like JC virus. His study focuses on the intersection of Fingolimod and fields such as Dimethyl fumarate with connections in the field of Odds ratio, Discontinuation and Propensity score matching. His Randomized controlled trial research includes themes of Alternative medicine, Control, Clinically isolated syndrome and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial
K. P. Johnson;B. R. Brooks;J. A. Cohen;C. C. Ford.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L. Hauser;Emmanuelle Waubant;Douglas L. Arnold;Timothy Vollmer.
The New England Journal of Medicine (2008)
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†
Kathleen Hawker;Paul O'Connor;Mark S. Freedman;Peter A. Calabresi.
Annals of Neurology (2009)
Proposed diagnostic criteria and nosology of acute transverse myelitis
G. Barnes;S. Benjamin;J. D. Bowen;N. Cutter.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery.
Lancet Neurology (2014)
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
Kenneth P. Johnson;B. R. Brooks;Jeffrey A Cohen;C. C. Ford.
Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
Timothy Vollmer;Lyndon Key;Valerie Durkalski;William Tyor;William Tyor.
The Lancet (2004)
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Dennis D. Spencer;Dennis D. Spencer;Richard J. Robbins;Frederick Naftolin;Frederick Naftolin;Kenneth L. Marek;Kenneth L. Marek.
The New England Journal of Medicine (1992)
Prevalence and treatment of spasticity reported by multiple sclerosis patients
M A Rizzo;O C Hadjimichael;J Preiningerova;T L Vollmer.
Multiple Sclerosis Journal (2004)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle.
Annals of Neurology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: